Pulmonx Corp
$ 1.53
-5.56%
05 Jun - close price
- Market Cap 68,424,000 USD
- Current Price $ 1.53
- High / Low $ 1.62 / 1.49
- Stock P/E N/A
- Book Value 1.08
- EPS -1.30
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.86 %
- 52 Week High 3.88
- 52 Week Low 1.13
About
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
Analyst Target Price
$3.40
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-29 | 2026-03-04 | 2025-11-12 | 2025-07-30 | 2025-04-30 | 2025-02-19 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-10-30 | 2023-08-02 |
| Reported EPS | -0.33 | -0.25 | -0.34 | -0.38 | -0.36 | -0.33 | -0.36 | -0.35 | -0.36 | -0.36 | -0.39 | -0.43 |
| Estimated EPS | -0.33 | -0.3948 | -0.42 | -0.4 | -0.4 | -0.45 | -0.45 | -0.43 | -0.46 | -0.41 | -0.43 | -0.44 |
| Surprise | 0 | 0.1448 | 0.08 | 0.02 | 0.04 | 0.12 | 0.09 | 0.08 | 0.1 | 0.05 | 0.04 | 0.01 |
| Surprise Percentage | 0% | 36.6768% | 19.0476% | 5% | 10% | 26.6667% | 20% | 18.6047% | 21.7391% | 12.1951% | 9.3023% | 2.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LUNG
2026-06-04 16:09:33
Pulmonx Corp's Chief Science & Technology Officer, Radhakrishnan Srikanth, sold 14,497 shares of common stock on June 1, 2026, across four transactions at $1.54 per share. These sales totaling $22,325 were made exclusively to cover tax withholding obligations stemming from the vesting of Restricted Stock Units granted between 2023 and 2026. This activity is considered a routine, tax-related insider transaction rather than a discretionary sale.
2026-06-04 03:38:58
Pulmonx general counsel David Lehman sold $22,474 worth of company stock to cover tax withholding obligations related to RSU vesting. This sale involved 14,594 shares at $1.54 each, aligning with the company's declining stock price. Pulmonx recently reported mixed Q1 2026 financial results, with better-than-expected EPS but a revenue miss, and InvestingPro tips indicate the company is burning cash and remains unprofitable.
2026-06-03 20:09:29
Pulmonx Corp's Chief Commercial Officer, Geoffrey Beran Rose, sold 8,023 shares of common stock at $1.54 per share on June 1, 2026. These sales were conducted to cover tax withholding obligations associated with the vesting of his Restricted Stock Units from 2023, 2024, 2025, and 2026. After these transactions, Rose still holds a substantial 463,956 shares, indicating that these were routine tax-related dispositions rather than a significant reduction of his stake in the company.
2026-06-03 20:09:29
Pulmonx Corp General Counsel David Aaron Lehman sold 14,594 shares of common stock at $1.54 per share on June 1, 2026. These sales were executed in four transactions solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 2023 and 2026. This activity is compensation- and tax-related, not a discretionary reduction in his investment.
2026-06-03 20:09:29
Pulmonx Corp CEO Glendon E. French III sold 56,149 shares of common stock on June 1-2, 2026, at prices between $1.54 and $1.57 per share. These sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on March 1, 2023, and are not considered discretionary trades. Following these transactions, French directly holds 1,178,162 shares and indirectly holds 918,198 shares through a family trust.
2026-06-02 15:09:50
Pulmonx (Nasdaq:LUNG) has granted equity awards totaling 84,300 Restricted Stock Units (RSUs) to 17 new employees hired in the first two quarters of 2026. These awards, issued under its 2025 Inducement Plan, are subject to a four-year vesting schedule, with one-fourth vesting on the one-year anniversary of the June 1, 2026 Grant Date, and the remainder vesting quarterly over the subsequent three years. This initiative aims to attract and retain talent in compliance with Nasdaq Listing Rule 5635(c)(4).
